FMP

FMP

Enter

SPPI - Spectrum Pharma...

photo-url-https://images.financialmodelingprep.com/symbol/SPPI.png

Spectrum Pharmaceuticals, Inc.

SPPI

NASDAQ

Inactive Equity

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and in-license agreement with ImmunGene, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is based in Boston, Massachusetts.

1.02 USD

-0.005 (-0.488%)

Historical Prices

From:

To:

We are unable to load the chart at this time.

fmp-logo

About

ceo

Mr. Thomas J. Riga

sector

Healthcare

industry

Biotechnology

exchange

NASDAQ

Description

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma. It has co-development, commercialization, and in-license...

CIK

0000831547

ISIN

US84763A1088

CUSIP

84763A108

Address

Pilot House – Lewis Wharf

Phone

617 586 3900

Country

US

Employee

86

IPO Date

Sep 26, 1996

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

SPPI Financial Summary

CIK

0000831547

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

84763A108

ISIN

US84763A1088

Country

US

Price

1.02

Beta

2.14

Volume Avg.

1.64M

Market Cap

210.38M

Shares

-

52-Week

0.32-1.57

DCF

1.62

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-2.85

P/B

-

Website

https://www.sppirx.com

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

Latest SPPI News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep